Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone in Metastatic Breast Cancer

This open-label phase 2 randomized clinical trial evaluates the safety and efficacy of vistusertib in combination with fulvestrant compared with fulvestrant alone or fulvestrant plus everolimus for women with hormone receptor–positive metastatic breast cancer.

Read the full article here

Related Articles